trelstar and Glioma

Seven children with central precocious puberty and either neurofibromatosis and/or optic gliomas were referred to the National Institutes of Health, Bethesda, Md, for evaluation and treatment with the long-acting luteinizing hormone releasing hormone analogue (LHRHa) D-Trp6-Pro9-NEt-LHRH. Only six of the seven children chose to receive treatment. Four children presented with neurofibromatosis, three of whom also had optic gliomas; the remaining three children had isolated optic gliomas, without other neurocutaneous stigmas. All had central precocious puberty mediated by activation of the hypothalamic-pituitary-gonadal axis. Six months of LHRHa therapy caused suppression of gonadotropin and sex steroid levels, stabilization or regression of secondary sexual characteristics, and decreases in growth velocity and the rate of bone age maturation. We conclude that LHRHa therapy is effective in the treatment of central precocious puberty secondary to neurofibromatosis and/or optic gliomas.

Topics: 17-alpha-Hydroxyprogesterone; Child; Child, Preschool; Chorionic Gonadotropin; Cortodoxone; Cranial Nerve Neoplasms; Estradiol; Female; Follicle Stimulating Hormone; Glioma; Gonadotropin-Releasing Hormone; Growth; Humans; Hydroxyprogesterones; Luteinizing Hormone; Male; Neurofibromatosis 1; Optic Nerve Diseases; Puberty, Precocious; Skin Neoplasms; Testosterone; Triptorelin Pamoate